Jump Search | Advanced Search
Home > Breaking News

Related quotes

44.32 + 1.47
9/2/03 4:00:00 PM ET

Wyeth warns doctors on Effexor antidepressant -WSJ
Reuters, 09.03.03, 1:26 AM ET


E-Mail Alerts  
  Medicines   Health
  Health and Medicine  
Enter E-Mail Address:                 FAQ  |  Privacy Policy
Mortgage Services from Homebound Mortgage
Apply For A Mortgage
Today’s Mortgage Rates
Home Equity
Mortgage Calculator
Free Credit Report
FHA & VA Mortgage Loans
Buyers Calculator
How Much Can You Borrow?
Should I Refinance?
Low Home Equity Rates

Please enter your name and email to begin:



Click 'Continue' to complete your subscription order.

eLibrary @ Forbes.com more > 
Research topics related to this story in the eLibrary news and magazine archives.
Medicines  Health 
Health and Medicine   

NEW YORK, Sept 3 (Reuters) - Drug maker Wyeth (nyse: WYE - news - people) has sent a two-page letter to doctors to warn them that its Effexor antidepressant may be more likely to cause children to consider suicide, the Wall Street Journal reported on Wednesday.

The company said it decided to notify doctors as a precaution, the paper reported.

"It's important safety information, and we thought it was important enough to provide in a letter to health-care physicians," Wyeth spokesman Douglas Petkus told the Journal. A Wyeth spokesperson was not immediately available to comment to Reuters.

The warning comes two months after the U.S. Food and Drug Administration warned about GlaxoSmithKline Plc's <GSK.L> Paxil use for children under 18 amid data suggesting it may lead to suicidal thoughts, said the paper. Petkus said Wyeth's warning was not related to the Paxil worries, according to the Journal.

Wyeth told the newspaper the data that prompted the warning letter were from several studies and that some were continuing, though it did not specify how many studies it had conducted on the drug and children, or how recent the studies were.

As of July, Effexor was Wyeth's best-selling product. The drug, which regulates two brain messenger chemicals, is becoming increasingly popular for patients who have failed to benefit from older therapies such as Eli Lilly & Co.'s (nyse: LLY - news - people) Prozac.

Effexor, which has not been approved for children, has been shown to be more effective than many standard depression treatments although it has been linked to more side effects.

Copyright 2003, Reuters News Service

Send comments

E-mail story


Ad Information       Forbes.com Wireless       Reprints / Permissions       Subscriber Services      
© 2003 Forbes.com™      All Rights Reserved       Privacy Statement       Terms, Conditions and Notices

Market data provided by Reuters. Disclaimer
Stock quotes are delayed at least 15 minutes for Nasdaq, at least 20 minutes for NYSE/AMEX.
U.S. indexes are delayed at least 15 minutes with the exception of S&P 500 which is real-time.
Forbes 40 Index powered by Telemet.
News may include latest headlines from Reuters.